How volume-based procurement of drugs works in China
National volume-based procurement in China buys a drug for all public medical institutions at once, with the quantity stated in the tender. Eleven national rounds had bought 490 drugs by October 2025.1 The rounds cover generics that have passed consistency evaluation and the originator drugs they copy. A negotiated drug within its agreement period is left out.2
The two governing documents
The General Office of the State Council issued the pilot plan on 1 January 2019 and an opinion for the permanent system on 22 January 2021.34
| Pilot plan of 2019 | Opinion of 2021 | |
|---|---|---|
| Area | 11 cities | The whole country |
| Drugs | Generic names with a generic that has passed consistency evaluation | Drugs on the basic insurance list with large volume and high spending, extended step by step |
| Volume | 60 to 70 per cent of annual use by public institutions in the pilot area | A base volume multiplied by an agreed share |
The pilot covered Beijing, Tianjin, Shanghai and Chongqing, with seven other large cities.3
Which drugs are bought
The opinion of 2021 gives priority to drugs that have passed the consistency evaluation of quality and efficacy for generics. Procurement starts once qualifying drugs reach a certain number or value.4
Generics that have passed the evaluation, originator drugs and reference products compete in one group under the generic name. No quality tiers are set among them, and protective or discriminatory terms are barred.4 Where more than three generics of a listed drug have passed the evaluation, procurement no longer selects products that have not passed it.4
Who takes part
| Party | Rule |
|---|---|
| Enterprises | A marketing authorisation holder that meets the requirements on quality, capacity and stable supply may in principle take part |
| Overseas holders | The enterprise legal person in China designated under the Drug Administration Law takes part for the holder |
| Public medical institutions | All must take part, including military institutions |
| Private institutions and pharmacies in the insurance network | They follow by reference, under their agreements |
An enterprise that takes part gives an undertaking on quality and supply.4
How volume and price are set
The base volume is assessed from the demand that institutions report, together with use in the previous year. The agreed share depends on the clinical features of the drug, the pattern of competition and the number of selected enterprises.4 The agreed volume is the product of the two, and it is published in the procurement documents.4
Enterprises take part voluntarily and quote their own prices. The highest valid bid is set from current market prices.4 Each selected enterprise has its agreed volume stated. Where several enterprises are selected for one generic name, the differences in price must be fair and reasonable.4
Beyond the agreed volume, public institutions are encouraged to buy selected products first. They may also buy other listed products at a suitable price on the provincial platform.4
Payment
The opinion of 2021 secures payment in three ways.4
- The medical institution settles with the enterprise by the end of the month after delivery and acceptance.
- The insurance fund prepays the institution at least 30 per cent of the annual agreed purchase value.
- Direct settlement between the fund and the enterprise is promoted.
The prepayment is set off step by step against the medical costs that the institution later claims from the fund.4
Use
Medical institutions must use selected drugs first and complete the agreed volume under the purchase contract. Physicians prescribe by generic name, and the prescribing system is set to recommend selected products first.4
Purchase and use of selected drugs count in the performance assessment of public institutions and of their heads. They are also a basis for setting the institution’s total insurance budget.4 Savings to the fund from procurement are shared with institutions as an incentive.4
The payment standard
For a procured drug on the insurance list, the payment standard is set on the selected price. Originator drugs, reference products and generics that have passed the evaluation share one standard under a generic name.4 A generic that has not passed may not have a higher standard than those that have.4
For a drug newly added to the national drug list through procurement, the selected price in the province is the payment standard. Where the market price of a product is above the standard, the patient bears the excess.5
What is left out
A report carried by the National Healthcare Security Administration in July 2025 sets out how the 55 drugs of the eleventh round were chosen.2
| Rule | Effect |
|---|---|
| Competition | The reference product and generics that passed evaluation must come from at least 7 enterprises in total |
| Negotiated drugs | A drug within its agreement period is left out |
| Bid drugs | A drug is left out in its first year on the list |
| Market size | A drug with purchases under RMB 100 million in 2024 is left out |
| Patents | A drug with a high risk of patent infringement is left out |
| Clinical risk | Drugs with special risks in use are left out for the round |
The report states the policy as new drugs outside procurement and procurement of drugs that are no longer new.2 Of 122 drugs that met the conditions, 55 formed the final list.2
The eleventh round
The eleventh round produced its results on 27 October 2025.1
| Figure | |
|---|---|
| Drugs | 55 |
| Institutions reporting volume | 46,000 |
| Products bidding | 794, from 445 enterprises |
| Products provisionally selected | 453, from 272 enterprises |
| Drugs bought across eleven rounds | 490 |
| Expected supply to patients | February 2026 |
Institutions could report volume by generic name or by brand, and 75 per cent of the volume reported by brand was met.1 Enterprises related by shareholding, entrusted production or transfer of approval documents were treated as one bidder.1
The round also kept drugs with a market under RMB 100 million out of procurement. It set an anchor price against extreme low bids and gave failed bidders a further chance to be selected.1
After the agreement ends
When a procurement agreement ends, the supplier, the agreed volume and the period are set again under the same principles. Where supply and demand or the market have changed materially, selection may be by bidding, price negotiation or inquiry.4
Below the national level
Provinces run procurement for drugs outside the national rounds, alone or in alliance with other provinces. Prefecture-level regions do the same for drugs outside the rounds above them.4 All public institutions in a province buy all the drugs they need on the provincial procurement platform.4
Questions people also ask
Are new drugs bought through volume-based procurement?
A negotiated drug within its agreement period is left out, and a bid drug is left out in its first year on the list.2
Must an originator drug compete with generics?
Originator drugs, reference products and generics that have passed evaluation compete in one group under the generic name.4
How much of the purchase value does the fund prepay?
The fund prepays at least 30 per cent of the annual agreed purchase value.4
How many drugs have the national rounds covered?
Eleven rounds had bought 490 drugs by October 2025.1
Can a foreign holder take part?
The enterprise legal person in China designated under the Drug Administration Law takes part for an overseas holder.4
Footnotes
-
National Healthcare Security Administration, release on the results of the eleventh national round of drug procurement, 28 October 2025. https://www.nhsa.gov.cn/art/2025/10/28/art_14_18369.html ↩ ↩2 ↩3 ↩4 ↩5 ↩6
-
21st Century Business Herald, report on the selection of drugs for the eleventh round, carried by the National Healthcare Security Administration on 16 July 2025. https://www.nhsa.gov.cn/art/2025/7/16/art_14_17307.html ↩ ↩2 ↩3 ↩4 ↩5
-
General Office of the State Council, Pilot Plan for National Centralised Procurement and Use of Drugs, Guo Ban Fa [2019] No. 2, 1 January 2019. https://www.gov.cn/zhengce/content/2019-01/17/content_5358604.htm ↩ ↩2
-
General Office of the State Council, Opinions on Making Centralised Volume-Based Procurement of Drugs Regular and Institutional, Guo Ban Fa [2021] No. 2, 22 January 2021. https://www.gov.cn/zhengce/content/2021-01/28/content_5583305.htm ↩ ↩2 ↩3 ↩4 ↩5 ↩6 ↩7 ↩8 ↩9 ↩10 ↩11 ↩12 ↩13 ↩14 ↩15 ↩16 ↩17 ↩18 ↩19 ↩20 ↩21 ↩22 ↩23
-
National Healthcare Security Administration and Ministry of Human Resources and Social Security, notice issuing the drug lists for 2025, Yi Bao Fa [2025] No. 33, 5 December 2025. https://www.nhsa.gov.cn/art/2025/12/7/art_104_18970.html ↩
Pothos builds longitudinal molecular profiles of individuals: whole-genome sequencing, single-cell RNA sequencing, and plasma proteomics, delivered as a detailed report, every data file, and stored cells. Build your profile.